West Virginia’s attorney general on April 4 urged a judge to hold Johnson & Johnson, Teva Pharmaceutical Industries Ltd., and AbbVie Inc.’s Allergen liable for causing a “tsunami” of opioid addiction in the state.

One day after U.S. bankruptcy judge Robert Drain approved an opioid settlement plan that locks Purdue Pharma’s Sackler family into paying about $6 billion into the nationwide fund, family members of those whose lives were devastated by addiction to drugs like OxyContin confronted the de facto face of the nation’s opioid crisis in court.

Teva

Teva Pharmaceutical Industries Ltd. reported solid results for full-year 2021, posting $15.9 billion in revenue including a gain of $4.1 billion from the fourth quarter. The company recently settled an opioid-related case in Texas and is preparing to pay as much as $3.6 billion in cash and medicine to settle the lawsuits filed against Teva.

The three largest U.S. drug distributors and drugmaker Johnson & Johnson agreed to pay $590 million to resolve claims by Native American tribes that the companies fueled an opioid epidemic in their communities, according to court filings.

Endo International agreed to pay up to $65 million to resolve claims by the state of Florida and local governments that the drugmaker helped fuel the U.S. opioid epidemic.

The state of Georgia decided to join a proposed $26 billion nationwide settlement resolving lawsuits alleging that three large drug distributors and drugmaker Johnson & Johnson fueled the deadly U.S. opioid epidemic.

Nevada agreed to back a proposed nationwide settlement worth up to $26 billion resolving lawsuits against three large drug distributors and the drugmaker Johnson & Johnson over the deadly U.S. opioid epidemic, the state’s attorney general said on January 4.

Specialty pharmaceutical company Collegium Pharmaceutical reached a $2.75 million agreement with the U.S. government to settle 27 pending lawsuits related to the opioid crisis and the company’s sale of Xtampza.

Although the U.S. Bankruptcy Court approved the OxyContin maker’s reorganization plan that freed the Sacklers from greater financial accountability and shielded them from additional lawsuits, the Department of Justice moved to block the Purdue Pharma bankruptcy deal.

U.S. states are racing to meet a deadline to commit to a $26 billion opioid settlement with three drug distributors and the drugmaker Johnson & Johnson, as some grapple with local resistance and concerns the amount is not large enough to address the damage done by an epidemic of addiction.